• Revenue of $4.68m from ongoing operations, down 57% on PCP
• Gross profit of $1.09 million*, down 74% on PCP
• Underlying EBITDA (excluding legal costs of approximately $2m) was negative $2.42 million

Jatcorp Limited (ASX: JAT) ('Jatcorp' or the 'Company), an Australian health and wellness consumer goods company, provides its quarterly activities and cash flow report for the quarter ending 31 December 2024 (Q2 FY25). Jatcorp has suspended sales of its Neurio® products in mainland China following an adverse ruling in a trademark dispute. The company is actively pursuing multiple legal avenues in China, Australia and New Zealand to protect its intellectual property, while minimising operational disruptions. Despite these challenges, Jatcorp has continued the execution of its growth strategy by accelerating its efforts towards market and channel expansion for the Moroka® brand, and Neurio® in markets where its intellectual property ownership is undisputed, such as Hong Kong and Australia. Jatcorp has onboarded approximately 30 retail outlets in Australia as local distributors of its Neurio® products and expanded the online distribution channels for its Moroka® products, achieving increased placement in approximately 15 third-party POP stores across leading platforms. The company also launched five new Moroka® products during the quarter. Manufacturing upgrades at the Company's ANMA facility in Melbourne were completed, including increasing the sachet production capacity by 70%, upgrading the automated packing equipment and installation of a laser QR code printer. Jatcorp showcased its manufacturing capabilities and product portfolio at the China International Import Expo (CIIE) in Shanghai, resulting in the onboarding of three new OEM customers.

Jatcorp CEO, Sunny Jian Xin Liang, said: 'We remain committed to defending our position against alleged malicious attempts to disrupt our operations. Our success in the New South Wales Supreme Court last April demonstrates the strength of our legal position and the recognition of our intellectual property rights. We are fully committed to replicating this outcome in China through rigorous legal action, while continuing to deliver growth via our diversified portfolio.'